Vinay Prasad, named to lead the FDA agency tasked with regulating vaccines and gene therapy, has made controversial comments regarding the government response to the COVID-19 pandemic.

Needham lowered the firm’s price target on Sarepta (SRPT) to $125 from $183 and keeps a Buy rating on the shares. The company ...

Biotech venture capital is risky business, inherently at the mercy of regulators and binary outcomes. Now it may face a new ...

Across hundreds of published papers, CBER’s new chief has argued for more stringent measures of assessing drugs for cancer ...

WASHINGTON — In his first address to FDA staff on Wednesday, Vinay Prasad emphasized his commitment to evidence, his ...

Dive deeper with STAT+. Gain unlimited access to expert analysis, newsletters, events, and news alerts.

The US Food and Drug Administration has chosen Dr Vinay Prasad, a professor at the University of California-San Francisco, to lead its Center for Biologics Evaluation and Research.

Momentum is building to scale back the current recommendation that all children over 6 months old get immunized against the ...

CRISPR Therapeutics faces challenges with a 20% stock drop, slow Casgevy commercialization, and regulatory hurdles. Read more ...

The independent experts will meet on May 22 to discuss updates to the COVID-19 vaccine for the upcoming season.

In his new role with the FDA, Dr. Vinay Prasad will oversee the regulation of costly drugs, including vaccines, gene ...

With a demand that vaccine boosters be tested against placebos, RFK Jr. puts an old antivaccine claim at the forefront of ...